Navigation Links
Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
Date:3/27/2012

PRINCETON, N.J., March 27, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2011.

Soligenix's revenues for the year ended December 31, 2011 were $7.7 million as compared to $1.9 million for the prior year. The increase in revenues was a result of a $5.0 million non-refundable license fee from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) in connection with the expansion of Soligenix's existing North American commercialization rights to orBec® and oral beclomethasone dipropionate (oral BDP) into the European Territory (the Sigma-Tau Agreement).

Soligenix's net loss for the year ended December 31, 2011 was $2.4 million, or $(0.22) per share, as compared to $7.4 million, or $(0.73) per share for the year ended December 31, 2010, representing a decreased loss of $5.0 million. This decreased loss is primarily attributable to the Sigma-Tau Agreement license fee received in the third quarter of 2011.

Research and development expenses for the full year 2011 were $6.3 million as compared to $6.0 million for the full year 2010. This increase is primarily attributable to payment of approximately $1.0 million in the form of cash and company stock to our orBec® licensor in connection with the Sigma-Tau Agreement offset by reduced spending resulting from the stoppage of our Phase 3 clinical trial of orBec® in the treatment of acute gastrointestinal Graft-versus Host disease (GI GVHD). General and administrative expenses for the full year 2011 were $2.2 million, compared to $2.2 for the full year 2010.

As of December 31, 2011, the Company's cash position was $6.0 million with working capital of $5.7 million.   

Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "In 2011 we saw the unfortunate stoppage of our Phase 3 trial of orBec® i
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
2. Soligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
3. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
4. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
5. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
6. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
7. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
10. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
11. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... June 8 CSL Limited (ASX: CSL) and Talecris Biotherapeutics, ... their merger agreement, announced on August 12, 2008, under which ... , , Dr. Brian McNamee, CEO and Managing Director ... Federal Trade Commission (FTC) resolved to block the transaction. ...
... Calif., June 8 Proteolix, Inc. today announced data from ... for the treatment of multiple myeloma at the 14th Congress ... Carfilzomib is the first in a new class of selective, ... of hematologic malignancies and solid tumors. , ...
... 8 /PRNewswire/ -- Pasteuria Bioscience announced that ... Agency (EPA) for Pasteuria usgae . This is ... spp., a natural bacteria prevalent in soil that have ... nematodes. , , "We,re very pleased to ...
Cached Biology Technology:CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 4Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association 5Pasteuria Bioscience Receives EPA Registration for Nematode Control 2
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
(Date:4/23/2014)... 23 2014) A team of researchers ... (hNSCs) into the brains of nonhuman primates and ... 24 months found that the hNSCs had differentiated ... cause tumors. , The study will be published ... but is currently freely available on-line as ...
(Date:4/23/2014)... have found evidence of an interaction between prenatal ... behavior in children, especially in girls. , "The ... to prenatal smoking will have behavioral problems. ... Boutwell, Assistant Professor at Sam Houston State University, ... the study. "One possible explanation for this ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2
... head. What do you do? You probably first move out of ... object is. Your brain is able to quickly switch from detecting ... is through a phenomenon called adaptation. A new study in ... Neuroscience details the biological basis of this ability for rapid ...
... , WASHINGTON, D.C., November 21, 2010 -- Jump ropes are ... But what about the underlying physics? How do jump ropes ... Aristoff and Howard Stone of Princeton University have built themselves ... parameters -- rope rotation rate, rope density, diameter, length, and ...
... The Innovative Vector Control Consortium (IVCC) has received $50 ... continue its work to develop new insecticides for the ... malaria, dengue and other neglected tropical diseases. ... grant of $50.7 million over five years from the ...
Cached Biology News:Study reveals neural basis of rapid brain adaptation 2Study reveals neural basis of rapid brain adaptation 3
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Anti-Goat HRP-AEC Cell & Tissue Staining Kit...
Biology Products: